共 46 条
- [41] Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studiesANTIVIRAL THERAPY, 2021, 26 (6-8) : 95 - 105Molina, Jean MichelEne, LuminitaCahn, PedroFaetkenheuer, GerdVan Wijngaerden, EricLombaard, JohanZakharova, NataliaVan Eygen, VeerleVanveggel, SimonVan Solingen-Ristea, Rodica
- [42] A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)O'Hara, Mark H.Wattenberg, Max MillerGarrido-Laguna, IgnacioO'Reilly, Eileen MaryYellin, Michael JayKeler, TiborGargano, Michele AnneNiles, NickDrees, JeremyBose, NanditaIglesias, Jose LuisBeatty, Gregory Lawrence
- [43] A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaEJHAEM, 2024, 5 (05): : 940 - 950Knop, StefanSzarejko, MonikaGrzasko, NorbertBringhen, SaraTrautmann-Grill, KarolinJurczyszyn, ArturVacca, AngeloKhandanpour, CyrusGamberi, BarbaraPour, LudekIversen, Katrine F.Stumpp, Michael T.Suter, CosimaDawson, Keith M.Zitt, ChristofLegenne, PhilippeStavropoulou, VaiaFey, Martin F.Leupin, NicolasGoldschmidt, Hartmut
- [44] Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35O'Malley, David M.Moore, Kathleen N.Vergote, IgnaceMartin, Lainie P.Gilbert, LucyMartin, Antonio GonzalezNepert, Dale L.Ruiz-Soto, RodrigoBirrer, Michael J.Matulonis, Ursula A.
- [45] Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia ( TWT-202)BLOOD, 2023, 142Jonas, Brian A.Yee, KarenMims, AliceKoller, Paul B.Brandwein, JosephRoboz, Gail J.Michelson, GlennLinh NguyenBray, Mark R.Roberts-Thomson, EmilySidhu, RogerBorthakur, Gautam
- [46] Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Bedard, Philippe L.Accordino, Melissa KateCervantes, AndresGambardella, ValentinaHamilton, Erika P.Italiano, AntoineJuric, DejanKalinsky, KevinKrop, Ian E.Oliveira, MafaldaSaura, CristinaSchmid, PeterTurner, Nicholas C.Varga, AndreeaShankar, NoopurSchutzman, JenniferRoyer Joo, StephanieMartin, Miguel ValeroJhaveri, Komal L.